Evidence map›Paper›PMID 40690378›Full record

ArticleeLife2025

Layilin regulates Treg motility and suppressive capacity in skin.

Victoire Gouirand, Sean Clancy, Courtney Macon, Jose Valle, Mariela Pauli, Hong-An Truong, Jarish Cohen, Maxime Kinet, Margaret M Lowe, Samuel J Lord and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eLife, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Victoire GouirandDepartment of Dermatology, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-2666-0061
Sean ClancyDepartment of Dermatology, University of California, San Francisco, San Francisco, United States.
Courtney MaconDepartment of Dermatology, University of California, San Francisco, San Francisco, United States.
Jose ValleTRex Bio Inc, South San Francisco, United States.
Mariela PauliTRex Bio Inc, South San Francisco, United States.
Hong-An TruongTRex Bio Inc, South San Francisco, United States.
Jarish CohenDepartment of Dermatology, University of California, San Francisco, San Francisco, United States.
Maxime KinetDepartment of Dermatology, University of California, San Francisco, San Francisco, United States.
Margaret M LoweDepartment of Dermatology, University of California, San Francisco, San Francisco, United States.
Samuel J LordDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-2785-989X
Kristen SkruberDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.
Hobart HarrisDepartment of Surgery, University of California, San Francisco, San Francisco, United States.
Esther KimDepartment of Surgery, University of California, San Francisco, San Francisco, United States.
Isaac NeuhausDepartment of Dermatology, University of California, San Francisco, San Francisco, United States.
Karin ReifTRex Bio Inc, South San Francisco, United States.ORCID https://orcid.org/0000-0001-5490-8389
Ali A ZarrinTRex Bio Inc, South San Francisco, United States.
R Dyche MullinsDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-0871-5479
Michael D RosenblumDepartment of Dermatology, University of California, San Francisco, San Francisco, United States.ORCID https://orcid.org/0000-0002-0462-5732

Funding

Research BaseP30DK063720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GERMAN, MICHAEL S · 2003 to 2019
$21.8M
BD FACSAria Fusion Cell SorterS10OD021822 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI LEE, MICHAEL R. · 2016 to 2016
$573k
Elucidating the Functional Role of Layilin Expression on Regulatory T cells in SkinR21AR072195 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ROSENBLUM, MICHAEL DAVID · 2017 to 2018
$384k
Cytek Aurora 5-Laser Spectral Flow CytometerS10OD026940 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SIMOES MARTINS BISPO, CLAUDIA · 2019 to 2019
$341k
NIAMS NIH HHS 5R21AR072195-02NIAMS NIH HHS R21 AR072195NIDDK NIH HHS P30 DK063720NIH HHS S10 OD021822NIH HHS S10 OD026940
6 · The paper itself

Abstract

Regulatory T cells (Tregs) are essential for maintaining immune tolerance in both lymphoid and non-lymphoid tissues. We discovered that layilin, a C-type lectin receptor, is predominantly expressed on Tregs in skin. Layilin was highly expressed on a subset of clonally expanded 'effector' Tregs in both healthy and psoriatic human skin. Layilin-expressing Tregs exhibited a transcriptional profile indicative of enhanced adhesion. Deletion of layilin in Tregs in mice in vivo resulted in significantly attenuated skin inflammation. Mechanistically, layilin enhanced in vitro human Treg adhesion via modulation of lymphocyte function-associated antigen-1, resulting in distinct cytoskeletal alterations consistent with enhanced focal adhesion and lamellipodia formation. Taken together, we define layilin as a critical regulator of Treg-suppressive capacity by modulating motility and adhesion in a non-lymphoid tissue.

Indexed as

Cell MovementSkinT-Lymphocytes, RegulatoryAnimalsCell AdhesionHumansMicecell adhesionimmunologyinflammationmouseregulatory T cellSkin

Identifiers

PMID40690378
PMCPMC12279370

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.